ClinicalTrials.gg
CompletedNCT00947856Updated Feb 2, 2017Results posted

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

A Phase 2 interventional study of brentuximab vedotin in Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Completed at 17 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2017-02-02.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
18th of 80
110 · median 52
Started
2009
with 2 others
Phase 2
41 of 80
8 open now
Registered
4th of 80
by date
Lead sponsor
12 of 80
Seagen Inc.

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 18th largest by enrollment, is one of 3 that started in 2009, is one of 41 in phase 2, and was the 4th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.

Read the detailed description

This is a multicenter, open-label study to evaluate single-agent brentuximab vedotin (SGN-35) treatment in patients who previously participated in a brentuximab vedotin study, including Studies SGN35-005 (NCT01100502), SGN35-007 (NCT01026233), and SGN35-008 (NCT01026415). Patients treated on this study (SGN35-006) could re-enroll on study if eligible. The study consisted of 2 arms, as follows:

  • Retreatment arm: Patients with CD30-positive hematologic malignancies who experienced a complete remission (CR) or partial remission (PR) with previous brentuximab vedotin treatment on a clinical study and subsequently experienced disease progression or relapse. The purpose of this arm was to assess safety and efficacy of retreatment with brentuximab vedotin.
  • Extension treatment arm: Patients with either CD30-positive hematologic or nonhematologic malignancies who completed treatment in a prior brentuximab vedotin study without unacceptable toxicity and experienced clinical benefit as assessed by the investigator. The purpose of this arm was to enable patients who participated in certain prior brentuximab vedotin trials to receive extension treatment and to assess patient safety and survival in the extension treatment setting.
03

Conditions studied

  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin

Keywords

  • Antibodies, Monoclonal
  • Antibody-Drug Conjugate
  • Antigens, CD30
  • Drug Therapy
  • Hematologic Diseases
  • Immunotherapy
  • Monomethylauristatin E
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in a previous brentuximab vedotin study.
  • CD30-positive hematologic .
  • At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For retreatment, patients must have previously achieved either complete or partial remission with brentuximab vedotin and experienced disease progression after discontinuing the prior brentuximab vedotin study.

Exclusion criteria

Exclusion Criteria:

Withdrew consent to participate in any prior brentuximab vedotin study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    BV Retreatment

    Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)

    Drug: brentuximab vedotin

  • Experimental
    BV Extension

    Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)

    Drug: brentuximab vedotin

Interventions

  • Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure

    Also known as: Adcetris

06

What researchers measure

Primary outcomes

  1. Objective Response Rate by Investigator

    Percentage of participants in the retreatment arm who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to approximately 38 months

  2. Adverse Events by Severity, Seriousness, and Relationship to Treatment

    Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on SGN35-006). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

    Time frame: up to 39 months

  3. Laboratory Abnormalities >/= Grade 3

    Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

    Time frame: Up to 39 months

Secondary outcomes

  1. Duration of Objective Response by Kaplan-Meier Analysis

    Duration of objective response (CR + PR) on retreatment, defined as time of initial response until disease progression or death

    Time frame: Up to 38 months

  2. Progression-free Survival by Kaplan-Meier Analysis

    Progression-free survival, defined as time from start of study treatment in the retreatment arm to disease progression per investigator or death due to any cause

    Time frame: Up to approximately 29 months

  3. Overall Survival

    Overall survival for both extension and retreatment arms, defined as time from start of study treatment to date of death due to any cause

    Time frame: Up to approximately 41 months

  4. Incidence of Antitherapeutic Antibodies

    Counts of participants with anti-brentuximab vedotin antibodies at any time during extension treatment on Study SGN35-006 or number of retreatment experiences with anti-brentuximab vedotin antibodies at any time during retreatment

    Time frame: Up to 39 months

07

Results

Posted May 26, 2014

Participant flow

Jul 2009 - Mar 2013

Treatment Period
Participant flow — Treatment Period
MilestoneBV ExtensionBV Retreatment
Started7832
Completed00
Not completed7832
Withdrew: Progressive disease3312
Withdrew: Adverse event159
Withdrew: Physician decision146
Withdrew: Study stopped by sponsor44
Withdrew: Withdrawal by subject121
Follow-up Period
Participant flow — Follow-up Period
MilestoneBV ExtensionBV Retreatment
Started7832
Completed279
Not completed5123
Withdrew: Study stopped by sponsor4020
Withdrew: Re-enrolled for retreatment23
Withdrew: Lost to follow-up70
Withdrew: Patient unavailable for site visits10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryObjective Response Rate by Investigator

Percentage of participants in the retreatment arm who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to approximately 38 months
Reported as:
Number · percentage of retreatment experiences
Objective Response Rate by Investigator
percentage of retreatment experiencesBV Retreatment - HLBV Retreatment - ALCLBV Retreatment - OtherBV Retreatment Total
Objective Response Rate by Investigator60 (36.1 to 80.9)91 (58.7 to 99.8)33 (0.8 to 90.6)68 (49.5 to 82.6)
PrimaryAdverse Events by Severity, Seriousness, and Relationship to Treatment

Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on SGN35-006). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

Time frame:
up to 39 months
Reported as:
Number · participants
Adverse Events by Severity, Seriousness, and Relationship to Treatment
participantsBV ExtensionBV Retreatment
Any TEAE7531
TEAE related to study drug6527
TEAE with severity grade >/=33716
Discontinued treatment due to adverse event139
Serious adverse event169
Serious adverse event related to study drug104
PrimaryLaboratory Abnormalities >/= Grade 3

Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.

Time frame:
Up to 39 months
Reported as:
Number · participants
Laboratory Abnormalities >/= Grade 3
participantsBV ExtensionBV Retreatment
Any >/= Grade 3 laboratory abnormality2912
Lymphocytes (low)168
Leukocytes (low)33
Neutrophils (low)73
Phosphate (low)73
Platelets (low)43
Aspartate aminotransferase (high)12
Glucose (high)32
Alanine aminotransferase (high)11
Bilirubin (high)01
Calcium (low)01
Hemoglobin (low)11
Potassium (low)01
Sodium (low)20
SecondaryDuration of Objective Response by Kaplan-Meier Analysis

Duration of objective response (CR + PR) on retreatment, defined as time of initial response until disease progression or death

Time frame:
Up to 38 months
Reported as:
Median · months
Duration of Objective Response by Kaplan-Meier Analysis
monthsBV Retreatment - HLBV Retreatment - ALCLBV Retreatment - OtherBV Retreatment Total
Duration of Objective Response by Kaplan-Meier Analysis9.2 (2.1 to NA)8.8 (1.4 to 12.9)NA (NA to NA)9.2 (6.6 to 12.9)
SecondaryProgression-free Survival by Kaplan-Meier Analysis

Progression-free survival, defined as time from start of study treatment in the retreatment arm to disease progression per investigator or death due to any cause

Time frame:
Up to approximately 29 months
Reported as:
Median · months
Progression-free Survival by Kaplan-Meier Analysis
monthsBV Retreatment - HLBV Retreatment - ALCLBV Retreatment - OtherBV Retreatment Total
Progression-free Survival by Kaplan-Meier Analysis9.9 (3.4 to 13.4)12.9 (3.4 to 18.5)4.4 (1.2 to NA)9.9 (4.4 to 13.4)
SecondaryOverall Survival

Overall survival for both extension and retreatment arms, defined as time from start of study treatment to date of death due to any cause

Time frame:
Up to approximately 41 months
Reported as:
Median · months
Overall Survival
monthsBV Extension TotalBV Retreatment - HLBV Retreatment - ALCLBV Retreatment - OtherBV Retreatment Total
Overall SurvivalNA (32.1 to NA)NA (11.4 to NA)NA (NA to NA)NA (5.1 to NA)NA (19.5 to NA)
SecondaryIncidence of Antitherapeutic Antibodies

Counts of participants with anti-brentuximab vedotin antibodies at any time during extension treatment on Study SGN35-006 or number of retreatment experiences with anti-brentuximab vedotin antibodies at any time during retreatment

Time frame:
Up to 39 months
Reported as:
Number · participants or experiences
Incidence of Antitherapeutic Antibodies
participants or experiencesBV ExtensionBV Retreatment
Incidence of Antitherapeutic Antibodies1512

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BV Extension—16/78 (20.5%)75/78 (96.2%)
BV Retreatment—9/32 (28.1%)31/32 (96.9%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventBV ExtensionBV Retreatment
PneumoniaInfections and infestations3/782/32
DehydrationMetabolism and nutrition disorders0/782/32
HyperglycaemiaMetabolism and nutrition disorders0/782/32
Peripheral sensory neuropathyNervous system disorders0/782/32
Mental status changesPsychiatric disorders1/782/32
Febrile neutropeniaBlood and lymphatic system disorders0/781/32
LeukocytosisBlood and lymphatic system disorders0/781/32
MethaemoglobinaemiaBlood and lymphatic system disorders0/781/32
Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders0/781/32
GlaucomaEye disorders0/781/32
Most frequent other events
Showing 10 of 68
Most frequent other events
EventBV ExtensionBV Retreatment
Peripheral sensory neuropathyNervous system disorders36/7817/32
DiarrhoeaGastrointestinal disorders15/7812/32
NauseaGastrointestinal disorders19/7812/32
FatigueGeneral disorders23/7811/32
Upper respiratory tract infectionInfections and infestations25/786/32
HeadacheNervous system disorders10/789/32
PyrexiaGeneral disorders20/788/32
Peripheral motor neuropathyNervous system disorders4/788/32
DyspnoeaRespiratory, thoracic and mediastinal disorders7/788/32
AnaemiaBlood and lymphatic system disorders7/787/32

Baseline characteristics

All participants who received treatment

Age, Customized
Age, Customized(years)BV ExtensionBV RetreatmentTotal
Median32 (15 to 78)37 (16 to 72)33.5 (15 to 78)
Gender
Gender(Participants)BV ExtensionBV RetreatmentTotal
Female351752
Male431558
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BV ExtensionBV RetreatmentTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander101
Black or African American7411
White662793
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)BV ExtensionBV RetreatmentTotal
France033
United States7829107
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)BV ExtensionBV RetreatmentTotal
0471259
1301848
2022
3-5000
Missing101
Disease diagnosis
Disease diagnosis(participants)BV ExtensionBV RetreatmentTotal
Hodgkin lymphoma (HL)682189
Systemic anaplastic large cell lymphoma (ALCL)8816
Other235
08

Study locations

17 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • University of Miami Miller School of Medicine / Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Loyola University Medical Center - Cardinal Bernadin Cancer Center
    Maywood, Illinois 60153, United States
  • St. Francis Medical Group Oncology & Hematology Specialists
    Indianapolis, Indiana 46237, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • The John Theurer Cancer Center, Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Columbia University Medical Center
    New York, New York 10019, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center /The University of Texas
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance / University of Washington Medical Center
    Seattle, Washington 98109-1023, United States
  • Hopital Saint-Louis/Service d'Hematologie
    Paris, Cedex 10 75475, France
09

References and documents

Publications

  • Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 Mar 19;7:24. doi: 10.1186/1756-8722-7-24. PubMed 24642247 ↗
  • Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17. PubMed 22510871 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2009
First posted
Jul 28, 2009
Start
Jul 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
May 26, 2014
Last update
Feb 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00947856
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Jul 28, 2009
Start date
Jul 2009
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
May 26, 2014
Last update
Feb 2, 2017

Study contacts

Laurie Grove, PA-C
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion